Generate a tailored SOP for Dr. David Preiss. Improve your application with a focused, well-structured draft.
David Preiss is a Professor of Metabolic Medicine at the University of Oxford, serving as a Senior Clinical Research Fellow at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). He has a strong focus on the prevention of cardiovascular microvascular disease with a specific emphasis on lipid modification in diabetes. His current research integrates clinical trials, epidemiological studies, and meta-analyses. Notable projects include ASCEND PLUS, a trial examining the effects of the GLP1 receptor agonist oral semaglutide on major cardiovascular events in participants with type 2 diabetes, and ORION-4, which investigates the effects of the LDL cholesterol-lowering drug inclisiran on major cardiovascular events. David completed his medical studies at the University of Pretoria, South Africa, and trained in medicine and biochemistry in Scotland, gaining recognition with awards including the Bellahouston Medal from the University of Glasgow for his doctoral research on links between glycaemia and cardiovascular disease. His contributions to clinical biochemistry have been acknowledged with the Royal College of Pathology’s Research Medal and the Rising Star Fellowship from the European Foundation for the Study of Diabetes.
Clinical Trial Service Unit & Epidemiological Studies Unit • Oxford, UK
Leading research on the effects of various drugs on cardiovascular health and conducting clinical trials.
Department of Politics and International Relations - Higher Level English requirement.